Glatiject is indicated for the treatment of relapsing forms of multiple sclerosis (MS) (see section 5.1 for important information on the population for which efficacy has been established). Glatiject is not indicated in primary or secondary progressive MS.

The initiation of Glatiject treatment should be supervised by a neurologist or a physician experienced in the treatment of MS.

Posology

The recommended dosage in adults is 40 mg of glatiramer acetate (one pre-filled syringe), administered as a subcutaneous injection three times a week with at least 48 hours apart.

At the present time, it is not known for how long the patient should be treated.

A decision concerning long term treatment should be made on an individual basis by the treating physician.

Renal impairment

Glatiject has not been specifically studied in patients with renal impairment (see section 4.4).

Elderly

Glatiject has not been specifically studied in the elderly.

Paediatric population

The safety and efficacy of glatiramer acetate in children and adolescents has not been established. There is not enough information available on the use of Glatiject 40 mg/ml TIW in children and adolescents below 18 years of age to make any recommendation for its use. Therefore, Glatiject 40 mg/ml TIW should not be used in this population.

Method of administration

Glatiject is for subcutaneous use.

Patients should be instructed in self-injection techniques and should be supervised by a healthcare professional the first time they self-inject and for 30 minutes after.

A different site should be chosen for every injection, so this will reduce the chances of any irritation or pain at the site of the injection. Sites for self-injection include the abdomen, arms, hips and thighs.

The CSYNC device is available should the patients want to make their injection with an injection device. The CSYNC device is an autoinjector to be used with Glatiject pre-filled syringes and it has not been tested with other pre-filled syringes. The CSYNC device should be used as recommended in the information provided by the device manufacturer.

Glatiject should only be administered subcutaneously. Glatiject should not be administered by intravenous or intramuscular routes.

The initiation of Glatiject treatment should be supervised by a neurologist or a physician experienced in the treatment of MS.

The treating physician should explain to the patient that a reaction associated with at least one of the following symptoms may occur within minutes of a Glatiject injection: vasodilatation (flushing), chest pain, dyspnoea, palpitations or tachycardia. The majority of these symptoms is short-lived and resolves spontaneously without any sequelae. Should a severe adverse event occur, the patient must immediately stop Glatiject treatment and contact his/her physician or any emergency doctor. Symptomatic treatment may be instituted at the discretion of the physician.

There is no evidence to suggest that any particular patient groups are at special risk for these reactions. Nevertheless, caution should be exercised when administering Glatiject to patients with pre-existing cardiac disorders. These patients should be followed up regularly during treatment.

Convulsions and/or anaphylactoid or allergic reactions have been reported rarely. Serious hypersensitivity reactions (e.g. bronchospasm, anaphylaxis or urticaria) may rarely occur. If reactions are severe, appropriate treatment should be instituted and Glatiject should be discontinued.

Glatiramer acetate-reactive antibodies were detected in patients' sera during daily chronic treatment with Glatiject. Maximal levels were attained after an average treatment duration of 3-4 months and, thereafter, declined and stabilised at a level slightly higher than baseline.

There is no evidence to suggest that these glatiramer acetate-reactive antibodies are neutralising or that their formation is likely to affect the clinical efficacy of Glatiject.

In patients with renal impairment, renal function should be monitored while they are treated with Glatiject. Whilst there is no evidence of glomerular deposition of immune complexes in patients, the possibility cannot be excluded.

Interaction between Glatiject and other medicinal products have not been formally evaluated.

There are no data on interaction with interferon beta.

An increased incidence of injection site reactions has been seen in Glatiject patients receiving concurrent administration of corticosteroids.

In vitro work suggests that glatiramer acetate in blood is highly bound to plasma proteins but that it is not displaced by, and does not itself displace, phenytoin or carbamazepine. Nevertheless, as Glatiject has, theoretically, the potential to affect the distribution of protein-bound substances, concomitant use of such medicinal products should be monitored carefully.

Pregnancy

Studies in animals have not shown reproductive toxicity (see section 5.3). Current data on the use of Glatiject 20 mg/ml in pregnant women indicate no malformative or feto/neonatal toxicity. Data on the use of Glatiject 40 mg/ml are consistent with these findings. To date, no relevant epidemiological data are available. As a precautionary measure, it is preferable to avoid the use of Glatiject during pregnancy unless the benefit to the mother outweighs the risk to the foetus.

Breastfeeding

It is unknown whether glatiramer acetate or its metabolites are excreted in human milk. In rats, no significant effects on offspring were observed except for a slight reduction in body weight gains in the offspring of mothers dosed during pregnancy and throughout lactation (see section 5.3).

A risk to the newborns/infants cannot be excluded. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Glatiject therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.

No studies on the effects on the ability to drive and use machines have been performed.

Most Glatiject safety data were accumulated for Glatiject 20 mg/ml administered as a subcutaneous injection once daily. This section presents accumulated safety data from four placebo-controlled trials with Glatiject 20 mg/ml administered once daily, and from one placebo-controlled trial with Glatiject 40 mg/ml administered three times a week.

A direct comparison of the safety between Glatiject 20 mg/ml (administered daily) and 40 mg/ml (administered three times per week) in the same study has not been performed.

Glatiject 20 mg/ml (administered once daily)

In all clinical trials with Glatiject 20 mg/ml, injection-site reactions were seen to be the most frequent adverse reactions and were reported by the majority of patients receiving Glatiject. In controlled studies, the proportion of patients reporting these reactions, at least once, was higher following treatment with Glatiject 20 mg/ml (70%) than placebo injections (37%). The most commonly reported injection-site reactions, which were more frequently reported in Glatiject 20 mg/ml vs. placebo-treated patients, were erythema, pain, mass, pruritus, oedema, inflammation and hypersensitivity.

A reaction, associated with at least one or more of the following symptoms, has been described as the immediate post-injection reaction: vasodilatation, chest pain, dyspnoea, palpitation or tachycardia. This reaction may occur within minutes of a Glatiject injection. At least one component of this immediate post-injection reaction was reported at least once by 31% of patients receiving Glatiject 20 mg/ml compared to 13% of patients receiving placebo.

All adverse reactions, which were more frequently reported in Glatiject 20 mg/ml vs. placebo-treated patients, are presented in the table below. This data was derived from four pivotal, double-blind, placebo-controlled clinical trials with a total of 512 patients treated with Glatiject 20 mg/day and 509 patients treated with placebo for up to 36 months. Three trials in relapsing-remitting MS (RRMS) included a total of 269 patients treated with Glatiject 20 mg/day and 271 patients treated with placebo for up to 35 months. The fourth trial in patients who have experienced a first clinical episode and were determined to be at high risk of developing clinically definite MS included 243 patients treated with Glatiject 20mg/day and 238 patients treated with placebo for up to 36 months.

* More than 2% (>2/100) higher incidence in the Glatiject treatment group than in the placebo group. Adverse reaction without the * symbol represents a difference of less than or equal to 2%.

§ The term 'injection site reactions' (various kinds) comprises all adverse events occurring at the injection site excluding injection site atrophy and injection site necrosis, which are presented separately within the table.

# Includes terms which relate to localized lipoatrophy at the injection sites.

In the fourth trial noted above, an open-label treatment phase followed the placebo-controlled period. No change in the known risk profile of Glatiject 20 mg/ml was observed during the open-label follow-up period of up to 5 years.

Rare (≥1/10,000 to <1/1,000) reports of anaphylactoid reactions were collected from MS patients treated with Glatiject in uncontrolled clinical trials and from post-marketing experience with Glatiject.

Glatiject 40 mg/ml (administered three times per week)

The safety of Glatiject 40 mg/ml was assessed based on a double-blind, placebo-controlled clinical trial in RRMS patients with a total of 943 patients treated with Glatiject 40 mg/ml three times per week, and 461 patients treated with placebo for 12 months.

In general, the kind of adverse drug reactions seen in patients treated with Glatiject 40 mg/ml administered three times per week were those already known and labelled for Glatiject 20 mg/ml administered daily. In particular, adverse injection site reactions (ISR) and immediate post-injection reactions (IPIR) were reported at lower frequency for Glatiject 40 mg/ml administered three times per week than for Glatiject 20 mg/ml administered daily (35.5 % vs. 70 % for ISRs and 7.8 % vs. 31 % for IPIRs, respectively).

Injection site reactions were reported by 36% of the patients on Glatiject 40 mg/ml compared to 5% on placebo. Immediate post-injection reaction was reported by 8% of the patients on Glatiject 40 mg/ml compared to 2% on placebo.

A few specific adverse reactions are noted:

• Anaphylactic response was seen rarely (≥1/10,000, <1/1,000) in MS patients treated with Glatiject 20 mg/ml in uncontrolled clinical trials and from post-marketing experience. It was reported by 0.3% of the patients on Glatiject 40 mg/ml (Uncommon: ≥ 1/1,000 to < 1/100).

• No injection site necrosis was reported.

• Skin erythema and pain in extremity, not labelled for Glatiject 20 mg/ml, were reported each by 2.1% of the patients on Glatiject 40 mg/ml (Common: ≥ 1/100 to < 1/10).

• Drug-induced liver injury and toxic hepatitis, also seen rarely in MS patients treated with Glatiject 20 mg/ml in post marketing surveillance, were each reported by one patient (0.1%) on Glatiject 40 mg/ml (Uncommon: ≥ 1/1,000 to < 1/100).

Reporting of suspected adverse reactions

A few cases of overdose with Glatiject (up to 300 mg glatiramer acetate) have been reported. These cases were not associated with any adverse reactions other than those mentioned in section “Undesirable effects”.

In case of overdose, patients should be monitored and the appropriate symptomatic and supportive therapy instituted.

Pharmacotherapeutic group: Antineoplastic and immunomodulating agents, other immunostimulants

ATC code: L03AX13

Mechanism of action

The mechanism by which glatiramer acetate exerts therapeutic effects in relapsing forms of MS is not fully elucidated but is presumed to involve modulation of immune processes. Studies in animals and MS patients suggest glatiramer acetate acts on innate immune cells, including monocytes, dendritic cells and B cells, which in turn modulate adaptive functions of B and T cells inducing anti-inflammatory and regulatory cytokine secretion. Whether the therapeutic effect is mediated by the cellular effects described above is not known because the pathophysiology of MS is only partially understood.

Clinical efficacy and safety

Relapsing-Remitting Multiple Sclerosis

Evidence supporting the effectiveness of Glatiject 40 mg/ml injection administered subcutaneously three times a week in decreasing the frequency of relapses derives from one 12-month placebo-controlled study.

In the pivotal clinical trial Relapsing-Remitting Multiple Sclerosis was characterised by either at least one documented relapse in the last 12 months, or at least two documented relapses in the last 24 months, or one documented relapse between the last 12 and 24 months with at least one documented T1-gadolinium enhancing lesion on magnetic resonance imaging performed the last 12 months.

The primary outcome measure was the total number of confirmed relapses. Secondary MRI outcomes included the cumulative number of new/enlarging T2 lesions and the cumulative number of enhancing lesions on T1-weighted images, both measured at months 6 and 12.

A total of 1404 patients were randomised in a 2:1 ratio to receive either Glatiject 40 mg/ml (n=943) or placebo (n=461). Both treatment groups were comparable with respect to baseline demographics, MS disease characteristics and MRI parameters. Patients had a median of 2.0 relapses in the 2 years prior to screening.

Compared to placebo, patients treated with Glatiject 40 mg/ml three times per week had meaningful and statistically significant reductions in the primary and secondary outcome measures which are consistent with the treatment effect of Glatiject 20 mg/ml administered daily.

The following table presents the values for the primary and secondary outcome measures for the intent-to-treat population:

*Absolute risk difference is defined as the difference between the adjusted mean ARR of GA 40 mg TIW and adjusted mean ARR of Placebo.

** Rate ratio is defined as the ratio between GA 40 mg TIW and Placebo adjusted mean rates.

A direct comparison of the efficacy and safety between Glatiject 20 mg/ml (administered daily) and 40 mg/ml (administered three times per week) in the same study has not been performed.

Glatiject 40 mg/mL: The proportion of patients with 3-month confirmed disability progression (CDP) was an exploratory endpoint in a 12-month placebo-controlled study (GALA). Three-month CDP was experienced by 3% and 3.5% of placebo- and Glatiject-treated patients, respectively (odds ratio, OR [95% CI]: 1.182 [0.661, 2.117] (p=0.5726)). Including the open-label extension of the study (up to 7 years), time to 6-month CDP was an exploratory endpoint. The hazard ratio (HR) [95% CI] for the intent to treat cohort, comparing the early start Glatiject group to the delayed start group was 0.892 [0.688, 1.157] (p=0.3898).

There is currently no evidence for the use of Glatiject in patients with primary or secondary progressive disease.

Pharmacokinetic studies in patients have not been performed. In vitro data and limited data from healthy volunteers indicate that with subcutaneous administration of glatiramer acetate, the active substance is readily absorbed and that a large part of the dose is rapidly degraded to smaller fragments already in subcutaneous tissue.

Preclinical data reveal no special hazard for humans based on studies of safety pharmacology, repeated dose toxicity, toxicity to reproduction, genotoxicity or carcinogenicity, beyond the information included in other sections of the SmPC. Due to the lack of pharmacokinetic data in humans, margins of exposure between humans and animals cannot be established.

Immune complex deposition in the glomeruli of the kidney was reported in a small number of rats and monkeys treated for at least 6 months. In a 2 years rat study, no indication of immune complex deposition in the glomeruli of the kidney was seen.

Anaphylaxis after administration to sensitised animals (guinea pigs or mice) was reported. The relevance of these data for humans is unknown.

Toxicity at the injection site was a common finding after repeated administration in animals.

Glatiramer acetate

Mannitol USP (Pyrogen Free Grade)

Water for injection USP

Nitrogen NF

In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products

·         Keep the pre-filled syringes in the outer carton, in order to protect from light.

·         Store in a refrigerator (2°C - 8°C)

·         Do not freeze

·         Keep the container in the outer carton in order to protect from light.

1ml Prefilled syringe

Pack Size: 12 PFS per Blister/Carton

Not all pack sizes may be marketed.

For single use only. Any unused product or waste material must be discarded.